| 货号 | 3395/1 |
| 别名 | (9S,10S,12R)-2,3,9,10,11,12-Hexahyd |
| 供应商 | Tocris |
| 生物活性 | Potent JAK2, FLT3 and TrkA inhibitor (IC50 values are 0.9, 3 and < 25 nM, respectively). Also inhibits Aurora kinase A and B (IC50 values are 8.1 and 2.3 nM, respectively) and prevents STAT5 phosphorylation (IC50 = 20 - 30 nM). Exhibits antiproliferative activity in vitro(IC50 = 30 - 100 nM in HEL92.1.7 cells) and is effective against myeloproliferative disorders in vivo. |
| 运输条件 | Blue Ice |
| 存放说明 | -20℃ |
| 纯度 | >99 % |
| 计算分子量 | 439.46 |
| 分子式 | C25H21N3O4 |
| 可溶性/溶解性 | Soluble to 100 mM in DMSO and to 25 mM in ethanol |
| CAS号 | 111358-88-4 |
| 参考文献 | Hexneret al (2008) Lestaurinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111 5663. PMID: 17984313. Weiselet al (2007) Effect of FLT3 inhibition on normal hematopoietic progenitor cells. Ann.N.Y.Acad.Sci. 1106 190. PMID: 17442779. Miknyoczkiet al (1999) The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann.N.Y.Acad.Sci. 880 252. PMID: 10415871. G |